Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

The goal of this prospective, interventional study is to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced NSCLC with EGFR ins20. The main question it aims to answer is: What are the mechanisms of acquired resistance to amivantamab monotherapy in this population of patients ? How anticipate the efficacy of subsequent systemic therapies ? After this information session, the participant will be asked to sign the study informed consent. A blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progress

Trial Details

NCT ID
NCT06247826
Phase
NA
Sponsor
Groupe Francais De Pneumo-Cancerologie
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Blood sampling
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Brest, France|48.39029,-4.48628
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • Grenoble, France|45.17869,5.71479

Key Eligibility Criteria

  • All patients with advanced NSCLC with EGFR ins20 receiving amivantamab as monotherapy in France under ATU or EAP;
  • Age ≥ 18 years;
  • Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR ins20;
  • Patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at pr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →